Literature DB >> 8095623

Disruption of sulphated glycosaminoglycans in intestinal inflammation.

S H Murch1, T T MacDonald, J A Walker-Smith, M Levin, P Lionetti, N J Klein.   

Abstract

We have studied the distribution and nature of sulphated glycosaminoglycans (GAGs) within normal and inflamed intestine. There is increasing evidence that these negatively charged polysaccharides, which both regulate the ability of albumin to leave the vasculature and inhibit thrombosis, may be affected by inflammatory cells and their products. We obtained samples of freshly resected intestinal tissue from eight controls, eleven patients with Crohn's disease, and six with ulcerative colitis. Sulphated GAGs were detected by means of a gold-conjugated poly-L-lysine probe, and the tissue density of anionic sites was assessed semiquantitatively by means of a Lennox graticule. In normal intestine there was staining in the vascular endothelium and the subepithelial basal lamina and throughout the extracellular matrix of the lamina propria and submucosa. Tissue from the patients with inflammatory bowel disease showed inflammation macroscopically and on histology. There were profound abnormalities of extracellular matrix GAGs, limited to the mucosa in ulcerative colitis and greatest in the submucosa in Crohn's disease. There was also substantial loss of GAGs from the subepithelial basal lamina in both disorders and from the vascular endothelium in submucosa in Crohn's disease. The extent of local GAG disruption was associated with the distribution of macrophages immunoreactive for tumour necrosis factor alpha and the activation marker RM 3/1. We suggest that inflammatory disruption of vascular and connective tissue GAGs may be an important pathogenetic mechanism, contributing to the leakage of protein and fluid, thrombosis, and tissue remodelling seen in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095623     DOI: 10.1016/0140-6736(93)90485-y

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  41 in total

1.  Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy.

Authors:  R Day; M Ilyas; P Daszak; I Talbot; A Forbes
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

2.  Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation.

Authors:  V Westphal; S Murch; S Kim; G Srikrishna; B Winchester; R Day; H H Freeze
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  Biochemical and immunohistochemical analysis of glycosaminoglycans in inflamed and non-inflamed intestinal mucosa of patients with Crohn's disease.

Authors:  Celso L R Belmiro; Heitor S P Souza; Celeste C S Elia; Morgana T L Castelo-Branco; Flavia R Silva; Rosane L Machado; Mauro S G Pavão
Journal:  Int J Colorectal Dis       Date:  2005-01-20       Impact factor: 2.571

4.  Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease.

Authors:  Silvana Geleff; Sebastian F Schoppmann; Georg Oberhuber
Journal:  Virchows Arch       Date:  2003-01-16       Impact factor: 4.064

Review 5.  Versatile role of heparanase in inflammation.

Authors:  Rachel Goldberg; Amichay Meirovitz; Nir Hirshoren; Raanan Bulvik; Adi Binder; Ariel M Rubinstein; Michael Elkin
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

6.  Efficacy of porcine secretin in children with autism and pervasive developmental disorder.

Authors:  Janet K Kern; S Van Miller; Patricia A Evans; Madhukar H Trivedi
Journal:  J Autism Dev Disord       Date:  2002-06

7.  Distribution and analysis of surface charge on brain endothelium in vitro and in situ.

Authors:  W L dos Santos; J Rahman; N Klein; D K Male
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

8.  Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function.

Authors:  Lars Bode; Camilla Salvestrini; Pyong Woo Park; Jin-Ping Li; Jeffrey D Esko; Yu Yamaguchi; Simon Murch; Hudson H Freeze
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

Review 9.  Heparanase in inflammation and inflammation-associated cancer.

Authors:  Amichay Meirovitz; Rachel Goldberg; Adi Binder; Ariel M Rubinstein; Esther Hermano; Michael Elkin
Journal:  FEBS J       Date:  2013-03-04       Impact factor: 5.542

10.  Microalbuminuria in inflammatory bowel disease.

Authors:  N Mahmud; J Stinson; M A O'Connell; T J Mantle; P W Keeling; J Feely; D G Weir; D Kelleher
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.